Previous Close | 77.73 |
Open | 77.65 |
Bid | 76.40 x 2200 |
Ask | 78.80 x 800 |
Day's Range | 76.41 - 77.56 |
52 Week Range | 71.59 - 94.20 |
Volume | |
Avg. Volume | 1,305,810 |
Market Cap | 14.113B |
Beta (5Y Monthly) | 0.49 |
PE Ratio (TTM) | 2,135.28 |
EPS (TTM) | 0.04 |
Earnings Date | Apr 27, 2022 - May 02, 2022 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 115.89 |
For many, the main point of investing is to generate higher returns than the overall market. But the main game is to...
BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced that the Company hired two pharmaceutical industry leaders in their respective areas of expertise. Humaira Serajuddin was named Senior Vice President, Chief Marketing Officer and Erin Burkhart was named Group Vice President, Chief Accounting Officer, filling two key strategic roles supporting BioMarin's growth goals.
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) today announced five platform presentations and one poster presentation on valoctocogene roxaparvovec, an investigational gene therapy for the treatment of adults with severe hemophilia A, at the World Federation of Hemophilia (WFH) 2022 World Congress from May 8-11 in Montreal, Canada.